South Korean deaths spark flu vaccine safety fears

South Korean officials refused to suspend the country’s seasonal flu inoculation programme on Oct 22, despite growing calls to do so following the deaths of at least 13 people who were vaccinated in recent days.

Health authorities said they have found no direct links between the deaths, which include a 17-year-old boy, and the vaccines being given under a programme to inoculate some 19 million teenagers and senior citizens for free.

“The number of deaths has increased, but our team sees low possibility that the deaths resulted from the shots,” Jeong Eun-kyeong, director of the Korea Disease Control and Prevention Agency, told parliament.

South Korea ordered 20% more flu vaccines this year to ward off what it calls a “twindemic” of people with flu developing potential Covid-19 complications, and overburdening hospitals over the winter.

The country’s free vaccine programme uses doses manufactured by local drug makers GC Pharma, SK Bioscience and Ilyang Pharmaceutical, along with France’s Sanofi and Britain’s Glaxosmithkline (GSK). The vaccines are distributed by local companies LG Chem and Boryung Biopharma, a unit of Boryung Pharm.

GC Pharma, LG Chem, SK Bioscience and Boryung declined to comment. Ilyang Pharmaceutical, Sanofi and GSK did not immediately reply to requests for comment.

It was not immediately clear if any of the South Korean-manufactured vaccines were exported, or whether those supplied by Sanofi and GSK were also being used in other countries.

The free programme has proved controversial from its launch last month. Its start was suspended for three weeks after it was discovered that some 5 million doses, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility. —